- Home
- >Perlara
Perlara
Perlara: building the YC for rare disease parents
Company
Website
http://perlara.comLocations
Oakland, CA, USA / Remote
Team Size
1
Industries
Healthcare, Drug Discovery and Delivery
About
Perlara 1.0 (Feb 2014 - Feb 2019) launched early R&D joint ventures called PerlQuests with highly motivated rare disease families, companies or impact investors. We screened gene-edited patient avatars for repurposable drugs in order to build a predictive R&D engine called ArkBase. We planned to monetize programs based on ArkBase predictions by selectively spinning out asset-centric clinical development NewCos.
Perlara 1.5 (March 2019 - April 2020) was the transition to a one-person virtual clinical development company and when the epalrestat and aripiprazole repurposing trials were launched at Mayo Clinic for the treatment of PMM2-CDG and NGLY1-CDDG, respectively.
Perlara 2.0 (May 2020 --> The first decentralized and distributed biotech
Founders
A list of all active founders
Sign-In
An account is required to download data from YCRM.
Almost There!
YCRM requires a one-time $30 payment to get access.
What You Get
- Unlimited downloads for 30 days
- 5000+ YC founders' email, LinkedIn, and Twitter
- Access to the latest YC batches
- Access to all CRM data enhancements
Payment Successful
Congrats! You now have unlimited access to the YCRM database for 30 days. If you have any questions or run into issues, please don't hesitate to reach out. We are here to help.
| Name | Title | |||
|---|---|---|---|---|
Ethan Perlstein | CEO | Sign-InAn account is required to download data from YCRM. Almost There!YCRM requires a one-time $30 payment to get access. What You Get
Payment SuccessfulCongrats! You now have unlimited access to the YCRM database for 30 days. If you have any questions or run into issues, please don't hesitate to reach out. We are here to help. |